Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Changzhou Qianhong Biopharma CO.,LTD (002550.SZ)
Changzhou, CN
Changzhou Qianhong Biopharma CO.,LTD operates as a key player in China's biopharmaceutical sector, specializing in the research, development, production, and distribution of biological drugs, with a core focus on enzyme and polysaccharide-based compounds. The company's product lineup features a variety of active pharmaceutical ingredients (APIs). These include a range of anticoagulants such as heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium, alongside pancreatin for digestive aid, asparaginase for antineoplastic applications, kallidinogenase kallikrein for treating microcirculation disorders, and heparinoid. Furthermore, Changzhou Qianhong provides ready-to-administer preparations, like pre-filled syringes of nadroparin calcium, enoxaparin sodium, and dalteparin sodium, all used as anticoagulants. It also supplies asparaginase injections for cancer treatment and heparin sodium injections to prevent blood clots. The company extends its reach through the export of its products internationally. Founded in 1971, Changzhou Qianhong Biopharma CO.,LTD maintains its headquarters in Changzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.64% | -3.21% | -10.72% | -18.74% | -24.91% | -19.47% | -11.84% | +12.43% | +57.46% | -23.27% | +29.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.0% Q1'26: -20.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+14.3% Q1'26: -47.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+25.9% Q1'26: +27.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+28.7% ★ Q1'26: +29.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+22.2% ★ Q1'26: +22.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.0% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.01× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
757.05M
est: 982.00M (-22.9%)
|
776.39M
est: 807.00M (-3.8%)
|
1.07B
est: 982.00M (+8.5%)
|
1.32B
est: 807.00M (+63.8%)
|
1.68B
est: 1.11B (+50.3%)
|
1.67B
est: 1.30B (+28.7%)
|
1.87B
est: 1.52B (+23.7%)
|
1.81B
est: 1.97B (-7.7%)
|
1.53B
est: 1.53B (+0.0%)
|
1.57B
est: 2.05B (-23.4%)
|
2.74B
2.74B – 2.74B
+33.4% YoY
|
3.28B
3.28B – 3.28B
+19.9% YoY
|
| EBITDA |
218.27M
est: 150.41M (+45.1%)
|
184.64M
est: 123.60M (+49.4%)
|
182.58M
est: 150.41M (+21.4%)
|
183.39M
est: 123.60M (+48.4%)
|
303.46M
est: 170.70M (+77.8%)
|
280.26M
est: 198.50M (+41.2%)
|
221.82M
est: 232.20M (-4.5%)
|
231.41M
est: 300.97M (-23.1%)
|
346.73M
est: 282.77M (+22.6%)
|
516.54M
est: 380.05M (+35.9%)
|
507.17M
507.17M – 507.17M
+33.4% YoY
|
608.34M
608.34M – 608.34M
+19.9% YoY
|
| EBIT |
197.78M
est: 113.53M (+74.2%)
|
157.10M
est: 93.30M (+68.4%)
|
121.21M
est: 113.53M (+6.8%)
|
121.99M
est: 93.30M (+30.7%)
|
237.99M
est: 128.85M (+84.7%)
|
210.01M
est: 149.84M (+40.2%)
|
152.38M
est: 175.27M (-13.1%)
|
162.19M
est: 227.18M (-28.6%)
|
282.12M
est: 225.52M (+25.1%)
|
450.64M
est: 303.11M (+48.7%)
|
404.49M
404.49M – 404.49M
+33.4% YoY
|
485.19M
485.19M – 485.19M
+19.9% YoY
|
| Net Income |
267.15M
est: 311.53M (-14.2%)
|
224.46M
est: 305.17M (-26.4%)
|
183.00M
est: 311.53M (-41.3%)
|
221.35M
est: 305.17M (-27.5%)
|
262.56M
est: 254.31M (+3.2%)
|
-132.02M
est: 279.74M (-147.2%)
|
181.08M
est: 356.03M (-49.1%)
|
181.86M
est: 228.88M (-20.5%)
|
356.03M
est: 348.95M (+2.0%)
|
398.80M
est: 411.26M (-3.0%)
|
411.26M
411.26M – 411.26M
+0.0% YoY
|
510.96M
510.96M – 510.96M
+24.2% YoY
|
| SGA |
296.81M
est: 275.49M (+7.7%)
|
331.77M
est: 226.39M (+46.5%)
|
345.13M
est: 275.49M (+25.3%)
|
429.26M
est: 226.39M (+89.6%)
|
477.71M
est: 312.66M (+52.8%)
|
483.04M
est: 363.58M (+32.9%)
|
587.29M
est: 425.29M (+38.1%)
|
521.42M
est: 551.25M (-5.4%)
|
423.58M
est: 396.31M (+6.9%)
|
291.47M
est: 532.65M (-45.3%)
|
710.81M
710.81M – 710.81M
+33.4% YoY
|
852.61M
852.61M – 852.61M
+19.9% YoY
|
| EPS |
0.21
est: 0.25 (-14.3%)
|
0.18
est: 0.24 (-25.0%)
|
0.14
est: 0.25 (-42.9%)
|
0.17
est: 0.24 (-27.3%)
|
0.21
est: 0.20 (+5.0%)
|
-0.11
est: 0.22 (-148.1%)
|
0.14
est: 0.28 (-48.3%)
|
0.14
est: 0.18 (-22.2%)
|
0.28
est: 0.28 (+0.0%)
|
0.32
est: 0.33 (-3.0%)
|
0.33
0.33 – 0.33
+0.0% YoY
|
0.41
0.41 – 0.41
+24.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 16.9K | 0.44% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 291.3K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 151.1K | 0.39% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.6K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 23.9K | 0.26% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 69.5K | 0.29% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.18M | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 77.4K | 0.28% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 13.1K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.18M | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aiqun Xiao | Audit Director | — | female |
| Chizhou Jiang | Deputy GM & Non-Independent Director | — | male |
| Juanwei Hua | Deputy Director of Project Implementation Office & Non-Employee Supervisor | — | male |
| Ke Wang | GM & Non-Independent Director | — | male |
| Lijun Wei | Chief Engineer & Director | — | male |
| Xiang Zhou | Deputy GM & Non-Independent Director | — | male |
| Yi Yao | Chief Financial Officer & Board Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002550.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
